3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Breast
1
Conditions
Breast Neoplasms
69
Triple Negative Breast Neoplasms
32
Ovarian Neoplasms
21
Neoplasm Metastasis
10
Prostatic Neoplasms
8
Pancreatic Neoplasms
7
Fanconi Anemia, Complementation Group D1
4
Fallopian Tube Neoplasms
4
Endometrial Neoplasms
4
Advanced Breast Cancer
4
Recurrence
3
Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Small Cell Lung Carcinoma
2
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Inflammatory Breast Neoplasms
2
Carcinoma, Renal Cell
2
Carcinoma, Ovarian Epithelial
2
Triple Negative Metastatic Breast Cancer
1
Thyroid Neoplasms
1
Thrombocytosis
1
Stomach Neoplasms
1
Sarcoma
1
Radiation Injuries
1
Prostatic Neoplasms, Castration-Resistant
1
Primary Myelofibrosis
1
Previously Treated HER2-negative Breast Cancer Patients With Homologous Recombination Deficiency
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pathologic Complete Response
1
Ovarian
1
Interventions
belinostat
2
zanidatamab
1
veliparib
1
tucatinib
1
trilaciclib
1
trebananib
1
trastuzumab duocarmazine
1
talazoparib
1
sarilumab
1
pexidartinib
1
pertuzumab
1
pembrolizumab
1
patritumab
1
olaparib
1
niraparib
1
neratinib
1
ganitumab
1
durvalumab
1
dostarlimab
1
cemiplimab
1
abemaciclib
1
Trastuzumab
1
Standard of Care
1
STA 9090
1
SGN-LIV1A
1
Paclitaxel
1
Nivolumab
1
Mass Spectrometry
1
MK 2206
1
Letrozole
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Hemangiosarcoma
×
olaparib
×
Breast
×
Clear all
NCT01042379
2026-05-06
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2
Recruiting
5,000 enrolled